Arrowhead Pharmaceuticals Stock Outlook Optimistic
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ARWR?
Source: CNBC
- Clinical Trial Data Release: Arrowhead Pharmaceuticals is set to release phase three clinical trial data for its RNA interference therapeutic Plozasiran, aimed at treating severe hypertriglyceridemia, in Q3 2026, which is expected to drive stock price increases as the market opportunity remains underappreciated.
- Analyst Rating Upgrade: Morgan Stanley upgraded Arrowhead's stock rating from equal weight to overweight and raised its price target from $78 to $100, implying a 44.4% upside from Monday's close, reflecting strong confidence in the company's future performance.
- Strong Stock Performance: Arrowhead's stock has surged over 473% in the past year, indicating robust market demand for its products and investor confidence, with analysts believing this momentum will continue.
- Market Consensus Support: Among the 13 analysts covering the stock, 10 have assigned a buy or strong buy rating, indicating a widespread positive outlook on Arrowhead's growth potential, further bolstering investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARWR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARWR
Wall Street analysts forecast ARWR stock price to rise
11 Analyst Rating
8 Buy
3 Hold
0 Sell
Moderate Buy
Current: 69.250
Low
35.00
Averages
82.00
High
110.00
Current: 69.250
Low
35.00
Averages
82.00
High
110.00
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Arrowhead Pharmaceuticals Stock Outlook Optimistic
- Clinical Trial Data Release: Arrowhead Pharmaceuticals is set to release phase three clinical trial data for its RNA interference therapeutic Plozasiran, aimed at treating severe hypertriglyceridemia, in Q3 2026, which is expected to drive stock price increases as the market opportunity remains underappreciated.
- Analyst Rating Upgrade: Morgan Stanley upgraded Arrowhead's stock rating from equal weight to overweight and raised its price target from $78 to $100, implying a 44.4% upside from Monday's close, reflecting strong confidence in the company's future performance.
- Strong Stock Performance: Arrowhead's stock has surged over 473% in the past year, indicating robust market demand for its products and investor confidence, with analysts believing this momentum will continue.
- Market Consensus Support: Among the 13 analysts covering the stock, 10 have assigned a buy or strong buy rating, indicating a widespread positive outlook on Arrowhead's growth potential, further bolstering investor confidence.
See More
Latest Wall Street Ratings Overview
- Cybersecurity Investment Opportunity: Berenberg initiates coverage on Palo Alto Networks with a buy rating, highlighting its status as a 'best-in-class' player in cybersecurity, combining multiple growth engines and strong product breadth, which is expected to attract more investor interest in its sustained growth potential.
- Optimistic Tesla Outlook: Bank of America reiterates Tesla as a buy, anticipating that the upcoming Q1 earnings report will focus on its robotaxi deployments aimed at disrupting the rideshare market and capturing a portion of the $1 trillion market opportunity, showcasing its strategic advantage amid increasing competition.
- Packaging Industry Growth Potential: Raymond James upgrades Ball Corp to outperform, citing the company's strong performance in cost pass-throughs and structural support for the beverage sector, predicting it will achieve outsized growth compared to its packaging peers.
- Biopharma Market Prospects: Canaccord initiates AbbVie with a buy rating and a price target of $262, emphasizing its position as a 'core holding' and showcasing its strong growth potential and market appeal in the biopharmaceutical sector.
See More
Arrowhead's Plozasiran Significantly Reduces TG Levels in Hypertriglyceridemia Patients
- Significant Efficacy: In a two-year open-label extension study, patients with severe hypertriglyceridemia treated with plozasiran achieved an 83% median reduction in triglycerides, with 96% reaching levels below 500 mg/dL, significantly lowering the risk of acute pancreatitis and demonstrating the drug's potential therapeutic value.
- Good Safety Profile: No acute pancreatitis events occurred during the study, and plozasiran's safety profile remained consistent with earlier trials, indicating good tolerability in high-risk patients and providing confidence for future clinical applications.
- Lipoprotein Improvements: Favorable improvements in atherogenic lipoproteins, including remnant cholesterol and non-HDL cholesterol, were observed, further supporting plozasiran as an effective option for managing hypertriglyceridemia.
- Future Outlook: Arrowhead plans to complete Phase 3 studies like SHASTA-3 and SHASTA-4 by mid-2026 and intends to submit a supplemental New Drug Application to the FDA by the end of 2026, reflecting the company's strong confidence in plozasiran's market potential.
See More
Ionis Pharmaceuticals Lowers Tryngolza Price to Enhance Competitive Positioning
- Pricing Strategy: Ionis Pharmaceuticals has lowered the price of Tryngolza ahead of the sHTG decision, with analysts suggesting that this move will enhance sales potential and attract more patients, thereby increasing market share.
- Sales Potential Increase: By reducing the price, Ionis aims to stand out in a competitive market, with analysts predicting that this action will significantly boost Tryngolza's sales over the coming quarters, further solidifying its position in the treatment landscape.
- Competitive Positioning Optimization: This price adjustment is not only a response to market demand but may also prompt competitors to reassess their pricing strategies, potentially impacting the overall industry price structure, allowing Ionis to gain a larger market advantage.
- Market Reaction Expectations: Analysts are generally optimistic about Tryngolza's market prospects, believing that the price reduction will enhance patient acceptance and drive sales growth, indicating Ionis's keen awareness of market dynamics.
See More
WVE-007 Trial Data Triggers Stock Volatility
- Trial Results: Wave Life Sciences reported that participants administered a single 240 mg dose of WVE-007 experienced a 0.9% weight reduction in the early trial phase, falling short of market expectations of 2% to 3%, which led to a nearly 50% drop in its stock price on Thursday.
- Market Reaction Analysis: Jones Research attributed WVE's stock decline primarily to the lower-than-expected weight loss, although the drug showed clinically meaningful reductions in visceral fat and waist circumference, with analysts cautiously optimistic about its potential utility in elderly or metabolic disease patients.
- Competitive Drug Comparison: Unlike traditional GLP-1 drugs that often lead to muscle loss, Arrowhead's obesity candidates ARO-INHBE and ARO-ALK7 aim to reduce body fat while preserving lean mass, which may provide a competitive edge, although current data comparisons are limited.
- Investor Sentiment Shift: While Wave's update appears largely priced in and Arrowhead's price target was lowered to $81, retail sentiment around ARWR shifted from neutral to bullish, indicating growing confidence in its future potential.
See More
Johnson & Johnson Divests from 3 Biotech Companies While Retaining Investments in Potential Acquisition Candidates
Johnson & Johnson's Holdings Report: The company has restated its fourth-quarter holdings report, which was filed last week.
Exit from Biotechs: Johnson & Johnson has exited three biotech companies as part of its portfolio adjustments.
Retention of Stakes: Despite the exits, the company has retained its stakes in several rumored acquisition targets.
Strategic Moves: These actions indicate a strategic shift in Johnson & Johnson's investment approach within the biotech sector.
See More
Arrowhead Pharmaceuticals Stock Outlook Optimistic
- Clinical Trial Data Release: Arrowhead Pharmaceuticals is set to release phase three clinical trial data for its RNA interference therapeutic Plozasiran, aimed at treating severe hypertriglyceridemia, in Q3 2026, which is expected to drive stock price increases as the market opportunity remains underappreciated.
- Analyst Rating Upgrade: Morgan Stanley upgraded Arrowhead's stock rating from equal weight to overweight and raised its price target from $78 to $100, implying a 44.4% upside from Monday's close, reflecting strong confidence in the company's future performance.
- Strong Stock Performance: Arrowhead's stock has surged over 473% in the past year, indicating robust market demand for its products and investor confidence, with analysts believing this momentum will continue.
- Market Consensus Support: Among the 13 analysts covering the stock, 10 have assigned a buy or strong buy rating, indicating a widespread positive outlook on Arrowhead's growth potential, further bolstering investor confidence.
See More
Latest Wall Street Ratings Overview
- Cybersecurity Investment Opportunity: Berenberg initiates coverage on Palo Alto Networks with a buy rating, highlighting its status as a 'best-in-class' player in cybersecurity, combining multiple growth engines and strong product breadth, which is expected to attract more investor interest in its sustained growth potential.
- Optimistic Tesla Outlook: Bank of America reiterates Tesla as a buy, anticipating that the upcoming Q1 earnings report will focus on its robotaxi deployments aimed at disrupting the rideshare market and capturing a portion of the $1 trillion market opportunity, showcasing its strategic advantage amid increasing competition.
- Packaging Industry Growth Potential: Raymond James upgrades Ball Corp to outperform, citing the company's strong performance in cost pass-throughs and structural support for the beverage sector, predicting it will achieve outsized growth compared to its packaging peers.
- Biopharma Market Prospects: Canaccord initiates AbbVie with a buy rating and a price target of $262, emphasizing its position as a 'core holding' and showcasing its strong growth potential and market appeal in the biopharmaceutical sector.
See More
Arrowhead's Plozasiran Significantly Reduces TG Levels in Hypertriglyceridemia Patients
- Significant Efficacy: In a two-year open-label extension study, patients with severe hypertriglyceridemia treated with plozasiran achieved an 83% median reduction in triglycerides, with 96% reaching levels below 500 mg/dL, significantly lowering the risk of acute pancreatitis and demonstrating the drug's potential therapeutic value.
- Good Safety Profile: No acute pancreatitis events occurred during the study, and plozasiran's safety profile remained consistent with earlier trials, indicating good tolerability in high-risk patients and providing confidence for future clinical applications.
- Lipoprotein Improvements: Favorable improvements in atherogenic lipoproteins, including remnant cholesterol and non-HDL cholesterol, were observed, further supporting plozasiran as an effective option for managing hypertriglyceridemia.
- Future Outlook: Arrowhead plans to complete Phase 3 studies like SHASTA-3 and SHASTA-4 by mid-2026 and intends to submit a supplemental New Drug Application to the FDA by the end of 2026, reflecting the company's strong confidence in plozasiran's market potential.
See More
Ionis Pharmaceuticals Lowers Tryngolza Price to Enhance Competitive Positioning
- Pricing Strategy: Ionis Pharmaceuticals has lowered the price of Tryngolza ahead of the sHTG decision, with analysts suggesting that this move will enhance sales potential and attract more patients, thereby increasing market share.
- Sales Potential Increase: By reducing the price, Ionis aims to stand out in a competitive market, with analysts predicting that this action will significantly boost Tryngolza's sales over the coming quarters, further solidifying its position in the treatment landscape.
- Competitive Positioning Optimization: This price adjustment is not only a response to market demand but may also prompt competitors to reassess their pricing strategies, potentially impacting the overall industry price structure, allowing Ionis to gain a larger market advantage.
- Market Reaction Expectations: Analysts are generally optimistic about Tryngolza's market prospects, believing that the price reduction will enhance patient acceptance and drive sales growth, indicating Ionis's keen awareness of market dynamics.
See More
WVE-007 Trial Data Triggers Stock Volatility
- Trial Results: Wave Life Sciences reported that participants administered a single 240 mg dose of WVE-007 experienced a 0.9% weight reduction in the early trial phase, falling short of market expectations of 2% to 3%, which led to a nearly 50% drop in its stock price on Thursday.
- Market Reaction Analysis: Jones Research attributed WVE's stock decline primarily to the lower-than-expected weight loss, although the drug showed clinically meaningful reductions in visceral fat and waist circumference, with analysts cautiously optimistic about its potential utility in elderly or metabolic disease patients.
- Competitive Drug Comparison: Unlike traditional GLP-1 drugs that often lead to muscle loss, Arrowhead's obesity candidates ARO-INHBE and ARO-ALK7 aim to reduce body fat while preserving lean mass, which may provide a competitive edge, although current data comparisons are limited.
- Investor Sentiment Shift: While Wave's update appears largely priced in and Arrowhead's price target was lowered to $81, retail sentiment around ARWR shifted from neutral to bullish, indicating growing confidence in its future potential.
See More
Johnson & Johnson Divests from 3 Biotech Companies While Retaining Investments in Potential Acquisition Candidates
Johnson & Johnson's Holdings Report: The company has restated its fourth-quarter holdings report, which was filed last week.
Exit from Biotechs: Johnson & Johnson has exited three biotech companies as part of its portfolio adjustments.
Retention of Stakes: Despite the exits, the company has retained its stakes in several rumored acquisition targets.
Strategic Moves: These actions indicate a strategic shift in Johnson & Johnson's investment approach within the biotech sector.
See More
